$ELOX
Eloxx Pharmaceuticals, Inc.

2018 Q2 Form 10-Q Financial Statement

#000119312518159256 Filed on May 10, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2018 Q1 2017 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.560M $3.390M $220.0K
YoY Change 2231.71% 1440.91% -33.33%
% of Gross Profit
Research & Development $4.150M $4.394M $2.355M
YoY Change 59.92% 86.58% 308.54%
% of Gross Profit
Depreciation & Amortization $25.00K $21.00K $6.000K
YoY Change 257.14% 250.0% -70.0%
% of Gross Profit
Operating Expenses $13.54M $8.548M $2.632M
YoY Change 326.01% 224.77% 356.59%
Operating Profit -$13.54M -$8.548M -$2.632M
YoY Change 326.01% 224.77% -46.16%
Interest Expense -$54.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net $137.0K -$43.00K -$1.420M
YoY Change -119.6% -96.97% -291.89%
Pretax Income -$13.41M -$8.590M -$2.066M
YoY Change 567.16% 315.77% -40.62%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$13.41M -$8.591M -$2.678M
YoY Change 245.69% 220.8% -13.03%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$421.2K -$312.0K -$1.754M
COMMON SHARES
Basic Shares Outstanding 33.43M shares 20.74M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $63.41M $18.29M $240.0K
YoY Change 211266.67% 7520.83% -84.31%
Cash & Equivalents $63.41M $18.29M $1.845M
Short-Term Investments
Other Short-Term Assets $560.0K $560.0K $30.00K
YoY Change 124.0% 1766.67% -62.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $63.97M $18.84M $272.3K
YoY Change 22746.43% 6820.25% -82.98%
LONG-TERM ASSETS
Property, Plant & Equipment $302.0K $314.0K $60.15K
YoY Change 504.0% 422.06% -45.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K
YoY Change -80.0%
Total Long-Term Assets $302.0K $314.0K $5.570M
YoY Change -94.57% -94.36% -37.84%
TOTAL ASSETS
Total Short-Term Assets $63.97M $18.84M $272.3K
Total Long-Term Assets $302.0K $314.0K $5.570M
Total Assets $64.27M $19.16M $5.842M
YoY Change 999.57% 227.87% -44.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.098M $2.173M $109.1K
YoY Change 995.01% 1890.91% 81.91%
Accrued Expenses $2.258M $3.478M $158.0K
YoY Change 583.62% 2101.36% -43.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $260.0K
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.356M $5.651M $1.057M
YoY Change 57.26% 434.39% 178.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.356M $5.651M $1.057M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $4.360M $5.650M $3.257M
YoY Change -12.34% 73.45% -33.79%
SHAREHOLDERS EQUITY
Retained Earnings -$60.96M -$47.55M -$119.5M
YoY Change -49.96% -60.19%
Common Stock $121.0M $61.06M $269.2K
YoY Change 41319.32% 22580.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $59.92M $13.51M $2.585M
YoY Change
Total Liabilities & Shareholders Equity $64.27M $19.16M $5.842M
YoY Change 999.57% 227.87% -44.68%

Cashflow Statement

Concept 2018 Q2 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$13.41M -$8.591M -$2.678M
YoY Change 245.69% 220.8% -13.03%
Depreciation, Depletion And Amortization $25.00K $21.00K $6.000K
YoY Change 257.14% 250.0% -70.0%
Cash From Operating Activities -$8.510M -$5.697M -$2.731M
YoY Change 1568.63% 108.6% 225.12%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K $57.00K $74.00K
YoY Change -22.97%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$40.00K -$57.00K -$96.00K
YoY Change -40.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 53.67M 0.000 2.460M
YoY Change 17790.0% -100.0%
NET CHANGE
Cash From Operating Activities -8.510M -5.697M -2.731M
Cash From Investing Activities -40.00K -57.00K -96.00K
Cash From Financing Activities 53.67M 0.000 2.460M
Net Change In Cash 45.12M -5.754M -367.0K
YoY Change -21585.71% 1467.85% -56.31%
FREE CASH FLOW
Cash From Operating Activities -$8.510M -$5.697M -$2.731M
Capital Expenditures -$40.00K $57.00K $74.00K
Free Cash Flow -$8.470M -$5.754M -$2.805M
YoY Change 1560.78% 105.13% 233.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33427238 shares
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2212000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1893000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
24506000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
787000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
54000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
60047000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1530000
CY2017Q4 us-gaap Assets
Assets
24784000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24049000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27527738 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27527738 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
274000
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
402000
CY2017Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24784000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3423000
CY2017Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
25000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
355000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
242000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
278000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
332000
CY2017Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
102000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38960000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
21361000
CY2017Q4 elox Contract Receivable Current
ContractReceivableCurrent
88000
CY2017Q4 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
704000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1845000
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3478000
CY2018Q1 us-gaap Assets Current
AssetsCurrent
18841000
CY2018Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2271000
CY2018Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
75000
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
60782000
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2173000
CY2018Q1 us-gaap Assets
Assets
19155000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18290000
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27527738 shares
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.30
CY2018Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
411615 shares
CY2018Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
411615 shares
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27527738 shares
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
274000
CY2018Q1 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
399000
CY2018Q1 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19155000
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5651000
CY2018Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
70000
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
445000
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q1 us-gaap Prepaid Insurance
PrepaidInsurance
292000
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
314000
CY2018Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
389000
CY2018Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
106000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47552000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
421500 shares
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
13504000
CY2018Q1 elox Contract Receivable Current
ContractReceivableCurrent
83000
CY2018Q1 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
808000
CY2018Q1 elox Number Of Equity Based Compensation Plans
NumberOfEquityBasedCompensationPlans
2 CompensationPlan
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2017Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
23000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11000
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14781825 shares
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-367000
CY2017Q1 us-gaap Depreciation
Depreciation
6000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.73
CY2017Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
277000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
63000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-822000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-644000
CY2017Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
22000
CY2017Q1 us-gaap Interest And Debt Expense
InterestAndDebtExpense
46000
CY2017Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
22000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-96000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2460000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
2632000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2731000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-2678000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2632000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
74000
CY2017Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2460000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2355000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
11000
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4205278 shares
CY2017Q1 elox Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-3062000
CY2017Q1 elox Accumulated Undeclared Dividend
AccumulatedUndeclaredDividend
-384000
CY2018Q1 dei Amendment Flag
AmendmentFlag
false
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
735000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4236656 shares
CY2018Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2055000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5759000
CY2018Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q1 us-gaap Depreciation
Depreciation
21000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-57000
CY2018Q1 dei Document Type
DocumentType
10-Q
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2018Q1 dei Document Period End Date
DocumentPeriodEndDate
2018-03-31
CY2018Q1 dei Entity Registrant Name
EntityRegistrantName
ELOXX PHARMACEUTICALS, INC.
CY2018Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001035354
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
8548000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5697000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-8591000
CY2018Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8548000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
57000
CY2018Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2018Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash
EffectOfExchangeRateOnCash
-5000
CY2018Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2480000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1585000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
643000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
90000
CY2018Q1 us-gaap Interest And Debt Expense
InterestAndDebtExpense
43000
CY2018Q1 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.08 pure
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4013000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
735000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.32
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
732212 shares
CY2018Q1 dei Trading Symbol
TradingSymbol
ELOX
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27527738 shares
CY2018Q1 elox Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-8591000
CY2018Q1 elox Number Of Geographic Regions
NumberOfGeographicRegions
2 Region
CY2018Q1 elox Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P4Y8M12D
CY2018Q1 elox Tax Cuts And Jobs Act Of2017 Incomplete Accounting Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit
10200000
CY2018Q1 elox Number Of Rare And Ultra Rare Disease Due To Premature Stoppage Of Codons
NumberOfRareAndUltraRareDiseaseDueToPrematureStoppageOfCodons
1800 Diseases

Files In Submission

Name View Source Status
0001193125-18-159256-index-headers.html Edgar Link pending
0001193125-18-159256-index.html Edgar Link pending
0001193125-18-159256.txt Edgar Link pending
0001193125-18-159256-xbrl.zip Edgar Link pending
d573032d10q.htm Edgar Link pending
d573032dex311.htm Edgar Link pending
d573032dex312.htm Edgar Link pending
d573032dex321.htm Edgar Link pending
d573032dex322.htm Edgar Link pending
elox-20180331.xml Edgar Link completed
elox-20180331.xsd Edgar Link pending
elox-20180331_cal.xml Edgar Link unprocessable
elox-20180331_def.xml Edgar Link unprocessable
elox-20180331_lab.xml Edgar Link unprocessable
elox-20180331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending